Friday, 16 October 2026European Markets

ITERA Stock Was 9.89% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with ITERA (ITERA.OL) jumping 9.89% to kr15.55 on Thursday while Oslo Børs Benchmark Index_GI fell 0.21% to kr1,201.49.

ITERA's last close was kr14.15, 2.41% below its 52-week high of kr14.50.

About ITERA

Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, ITERA has a trailing twelve months EPS of kr0.77.

PE Ratio

ITERA has a trailing twelve months price to earnings ratio of 20.19. Meaning, the purchaser of the share is investing kr20.19 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 138.07%.

Sales Growth

ITERA's sales growth is 21% for the ongoing quarter and 11.2% for the next.

Volume

Today's last reported volume for ITERA is 101503 which is 370.09% above its average volume of 21592.

Volatility

ITERA's last week, last month's, and last quarter's current intraday variation average was 0.63%, 0.36%, and 2.21%.

ITERA's highest amplitude of average volatility was 1.18% (last week), 2.39% (last month), and 2.21% (last quarter).

Yearly Top and Bottom Value

ITERA's stock is valued at kr15.55 at 22:33 EST, above its 52-week high of kr14.50.

More news about ITERA (ITERA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com